Augmentation therapy with α1-antitrypsin patterns of use and adverse events

James K. Stoller, Robert Fallat, Mark D. Schluchter, Ralph G. O'Brien, Jason T. Connor, Nicholas Gross, Kevin O'Neil, Robert Sandhaus, Ronald Crystal

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Study objectives: To describe patterns of prescribing augmentation therapy, and types and rates of adverse events in the National Heart, Lung, and Blood Institute Registry for Individuals with Severe Deficiency of Alpha1-Antitrypsin. Design: Observational cohort study with follow-up visits every 6 to 12 months for up to 7 years. Measurements: The rate and dosing frequency with which Registry participants were prescribed to receive augmentation therapy by their managing physicians, and the type and frequency of adverse events, classified in two ways: severity of self-reported symptoms, and actions taken as a consequence of the symptom. Results: Over the course of Registry follow-up, 66% (n = 747) of the participants received augmentation therapy at some time. In keeping with recommendations made in the 1989 American Thoracic Society (ATS) statement, 75% of participants with airflow obstruction at first visit (defined as FEV1 < 80% predicted) received augmentation therapy within 3 years, though some participants with FEV1 ≥ 80% predicted (14%) also received augmentation therapy. Among those with COPD for whom augmentation therapy was not prescribed, financial constraints were the reported cause in 30%. Observed patterns also varied from approved practice, in that dosing frequencies other than the US Food and Drug Administration-approved, once-weekly regimen were frequently prescribed. The overall rate of reported adverse events was 0.02 per patient-month, with 83% of participants reporting no events. This overall rate was composed of 16% considered mild events, 76% moderate events, and 9% severe events. Conclusions: We conclude that augmentation therapy was generally well tolerated and, consistent with ATS guidelines, physicians generally did not prescribe augmentation therapy for subjects with FEV1 ≥ 80% predicted. However, the large percentage of subjects with FEV1 <80% predicted not receiving augmentation therapy and the frequent use of 2- to 3-week or monthly dosing reflects variation of practice from suggested treatment guidelines.

Original languageEnglish
Pages (from-to)1425-1434
Number of pages10
JournalChest
Volume123
Issue number5
DOIs
Publication statusPublished - 1 May 2003
Externally publishedYes

Fingerprint

Registries
Therapeutics
Guidelines
National Heart, Lung, and Blood Institute (U.S.)
Physicians
United States Food and Drug Administration
Chronic Obstructive Pulmonary Disease
Observational Studies
Cohort Studies
Thorax

Keywords

  • Augmentation therapy
  • COPD
  • α-antiprotease
  • α-antitrypsin

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Stoller, J. K., Fallat, R., Schluchter, M. D., O'Brien, R. G., Connor, J. T., Gross, N., ... Crystal, R. (2003). Augmentation therapy with α1-antitrypsin patterns of use and adverse events. Chest, 123(5), 1425-1434. https://doi.org/10.1378/chest.123.5.1425

Augmentation therapy with α1-antitrypsin patterns of use and adverse events. / Stoller, James K.; Fallat, Robert; Schluchter, Mark D.; O'Brien, Ralph G.; Connor, Jason T.; Gross, Nicholas; O'Neil, Kevin; Sandhaus, Robert; Crystal, Ronald.

In: Chest, Vol. 123, No. 5, 01.05.2003, p. 1425-1434.

Research output: Contribution to journalArticle

Stoller, JK, Fallat, R, Schluchter, MD, O'Brien, RG, Connor, JT, Gross, N, O'Neil, K, Sandhaus, R & Crystal, R 2003, 'Augmentation therapy with α1-antitrypsin patterns of use and adverse events', Chest, vol. 123, no. 5, pp. 1425-1434. https://doi.org/10.1378/chest.123.5.1425
Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N et al. Augmentation therapy with α1-antitrypsin patterns of use and adverse events. Chest. 2003 May 1;123(5):1425-1434. https://doi.org/10.1378/chest.123.5.1425
Stoller, James K. ; Fallat, Robert ; Schluchter, Mark D. ; O'Brien, Ralph G. ; Connor, Jason T. ; Gross, Nicholas ; O'Neil, Kevin ; Sandhaus, Robert ; Crystal, Ronald. / Augmentation therapy with α1-antitrypsin patterns of use and adverse events. In: Chest. 2003 ; Vol. 123, No. 5. pp. 1425-1434.
@article{03e9c2c86bca4e2f9ca6555428f77df4,
title = "Augmentation therapy with α1-antitrypsin patterns of use and adverse events",
abstract = "Study objectives: To describe patterns of prescribing augmentation therapy, and types and rates of adverse events in the National Heart, Lung, and Blood Institute Registry for Individuals with Severe Deficiency of Alpha1-Antitrypsin. Design: Observational cohort study with follow-up visits every 6 to 12 months for up to 7 years. Measurements: The rate and dosing frequency with which Registry participants were prescribed to receive augmentation therapy by their managing physicians, and the type and frequency of adverse events, classified in two ways: severity of self-reported symptoms, and actions taken as a consequence of the symptom. Results: Over the course of Registry follow-up, 66{\%} (n = 747) of the participants received augmentation therapy at some time. In keeping with recommendations made in the 1989 American Thoracic Society (ATS) statement, 75{\%} of participants with airflow obstruction at first visit (defined as FEV1 < 80{\%} predicted) received augmentation therapy within 3 years, though some participants with FEV1 ≥ 80{\%} predicted (14{\%}) also received augmentation therapy. Among those with COPD for whom augmentation therapy was not prescribed, financial constraints were the reported cause in 30{\%}. Observed patterns also varied from approved practice, in that dosing frequencies other than the US Food and Drug Administration-approved, once-weekly regimen were frequently prescribed. The overall rate of reported adverse events was 0.02 per patient-month, with 83{\%} of participants reporting no events. This overall rate was composed of 16{\%} considered mild events, 76{\%} moderate events, and 9{\%} severe events. Conclusions: We conclude that augmentation therapy was generally well tolerated and, consistent with ATS guidelines, physicians generally did not prescribe augmentation therapy for subjects with FEV1 ≥ 80{\%} predicted. However, the large percentage of subjects with FEV1 <80{\%} predicted not receiving augmentation therapy and the frequent use of 2- to 3-week or monthly dosing reflects variation of practice from suggested treatment guidelines.",
keywords = "Augmentation therapy, COPD, α-antiprotease, α-antitrypsin",
author = "Stoller, {James K.} and Robert Fallat and Schluchter, {Mark D.} and O'Brien, {Ralph G.} and Connor, {Jason T.} and Nicholas Gross and Kevin O'Neil and Robert Sandhaus and Ronald Crystal",
year = "2003",
month = "5",
day = "1",
doi = "10.1378/chest.123.5.1425",
language = "English",
volume = "123",
pages = "1425--1434",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - Augmentation therapy with α1-antitrypsin patterns of use and adverse events

AU - Stoller, James K.

AU - Fallat, Robert

AU - Schluchter, Mark D.

AU - O'Brien, Ralph G.

AU - Connor, Jason T.

AU - Gross, Nicholas

AU - O'Neil, Kevin

AU - Sandhaus, Robert

AU - Crystal, Ronald

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Study objectives: To describe patterns of prescribing augmentation therapy, and types and rates of adverse events in the National Heart, Lung, and Blood Institute Registry for Individuals with Severe Deficiency of Alpha1-Antitrypsin. Design: Observational cohort study with follow-up visits every 6 to 12 months for up to 7 years. Measurements: The rate and dosing frequency with which Registry participants were prescribed to receive augmentation therapy by their managing physicians, and the type and frequency of adverse events, classified in two ways: severity of self-reported symptoms, and actions taken as a consequence of the symptom. Results: Over the course of Registry follow-up, 66% (n = 747) of the participants received augmentation therapy at some time. In keeping with recommendations made in the 1989 American Thoracic Society (ATS) statement, 75% of participants with airflow obstruction at first visit (defined as FEV1 < 80% predicted) received augmentation therapy within 3 years, though some participants with FEV1 ≥ 80% predicted (14%) also received augmentation therapy. Among those with COPD for whom augmentation therapy was not prescribed, financial constraints were the reported cause in 30%. Observed patterns also varied from approved practice, in that dosing frequencies other than the US Food and Drug Administration-approved, once-weekly regimen were frequently prescribed. The overall rate of reported adverse events was 0.02 per patient-month, with 83% of participants reporting no events. This overall rate was composed of 16% considered mild events, 76% moderate events, and 9% severe events. Conclusions: We conclude that augmentation therapy was generally well tolerated and, consistent with ATS guidelines, physicians generally did not prescribe augmentation therapy for subjects with FEV1 ≥ 80% predicted. However, the large percentage of subjects with FEV1 <80% predicted not receiving augmentation therapy and the frequent use of 2- to 3-week or monthly dosing reflects variation of practice from suggested treatment guidelines.

AB - Study objectives: To describe patterns of prescribing augmentation therapy, and types and rates of adverse events in the National Heart, Lung, and Blood Institute Registry for Individuals with Severe Deficiency of Alpha1-Antitrypsin. Design: Observational cohort study with follow-up visits every 6 to 12 months for up to 7 years. Measurements: The rate and dosing frequency with which Registry participants were prescribed to receive augmentation therapy by their managing physicians, and the type and frequency of adverse events, classified in two ways: severity of self-reported symptoms, and actions taken as a consequence of the symptom. Results: Over the course of Registry follow-up, 66% (n = 747) of the participants received augmentation therapy at some time. In keeping with recommendations made in the 1989 American Thoracic Society (ATS) statement, 75% of participants with airflow obstruction at first visit (defined as FEV1 < 80% predicted) received augmentation therapy within 3 years, though some participants with FEV1 ≥ 80% predicted (14%) also received augmentation therapy. Among those with COPD for whom augmentation therapy was not prescribed, financial constraints were the reported cause in 30%. Observed patterns also varied from approved practice, in that dosing frequencies other than the US Food and Drug Administration-approved, once-weekly regimen were frequently prescribed. The overall rate of reported adverse events was 0.02 per patient-month, with 83% of participants reporting no events. This overall rate was composed of 16% considered mild events, 76% moderate events, and 9% severe events. Conclusions: We conclude that augmentation therapy was generally well tolerated and, consistent with ATS guidelines, physicians generally did not prescribe augmentation therapy for subjects with FEV1 ≥ 80% predicted. However, the large percentage of subjects with FEV1 <80% predicted not receiving augmentation therapy and the frequent use of 2- to 3-week or monthly dosing reflects variation of practice from suggested treatment guidelines.

KW - Augmentation therapy

KW - COPD

KW - α-antiprotease

KW - α-antitrypsin

UR - http://www.scopus.com/inward/record.url?scp=0038216603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038216603&partnerID=8YFLogxK

U2 - 10.1378/chest.123.5.1425

DO - 10.1378/chest.123.5.1425

M3 - Article

VL - 123

SP - 1425

EP - 1434

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -